Invention Grant
- Patent Title: Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
-
Application No.: US15511973Application Date: 2015-09-17
-
Publication No.: US10577417B2Publication Date: 2020-03-03
- Inventor: Gregory Beatty , Boris Engels , Neeraja Idamakanti , Carl H. June , Andreas Loew , Michael C. Milone , Huijuan Song , Enxiu Wang , Qilong Wu
- Applicant: Novartis AG , The Trustees of the University of Pennsylvania
- Applicant Address: CH Basel US PA Philadelphia
- Assignee: Novartis AG,The Trustees of the University of Pennsylvania
- Current Assignee: Novartis AG,The Trustees of the University of Pennsylvania
- Current Assignee Address: CH Basel US PA Philadelphia
- Agency: Lando & Anastasi, LLP
- Priority: WOPCT/CN2014/086694 20140917; WOPCT/CN2014/090578 20141107
- International Application: PCT/US2015/050715 WO 20150917
- International Announcement: WO2016/044605 WO 20160324
- Main IPC: A61K35/17
- IPC: A61K35/17 ; C07K14/705 ; C07K16/28 ; C07K16/30 ; C07K14/725 ; C07K14/74 ; C12N5/0783

Abstract:
The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
Public/Granted literature
- US20170260268A1 TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY Public/Granted day:2017-09-14
Information query
IPC分类: